Biotech

CRISPR Therapeutics

CRISPR Therapeutics raises $337M Follow-on Offering at $8B valuation

$337M
Total Raised
Follow-on Offering
Latest Round
2013
Founded
500+
Employees
Aeschenvorstadt 36, Basel 4051, Switzerland
1 min read

Quick Facts

Valuation
$8B
Latest Round Size
$337M
Latest Round Date
September 2024

CRISPR Therapeutics: Follow-on Offering Funding Round

CRISPR Therapeutics has successfully raised $337M in Follow-on Offering funding, reaching a valuation of $8B.

Company Overview

Gene-based medicines using CRISPR/Cas9

Funding Details

The Follow-on Offering round was led by Versant Ventures, with participation from Bayer, Vertex Pharmaceuticals.

Company Information

  • Headquarters: Aeschenvorstadt 36, Basel 4051, Switzerland
  • Founded: 2013
  • Employees: 500+
  • Category: Biotech

Investment

CRISPR Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

  • Versant Ventures: Verified investor in Follow-on Offering
  • Bayer: Verified investor in Follow-on Offering
  • Vertex Pharmaceuticals: Verified investor in Follow-on Offering

Key Investors

Versant Ventures
Lead Investor
Verified investor in Follow-on Offering
Bayer
Investor
Verified investor in Follow-on Offering
Vertex Pharmaceuticals
Investor
Verified investor in Follow-on Offering

About the Author

Editorial Team
Editorial Team
Curated funding news from verified sources